Cargando…

IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform

The long-term prognosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is still unsatisfactory even after the emergence of tyrosine kinase inhibitors (TKIs) against chimeric BCR-ABL, and this is associated with the high incidence of genetic alterations of Ikaros family z...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harama, Daisuke, Yahata, Takashi, Kagami, Keiko, Abe, Masako, Ando, Norie, Kasai, Shin, Tamai, Minori, Akahane, Koshi, Inukai, Takeshi, Kiyokawa, Nobutaka, Ibrahim, Abd Aziz, Ando, Kiyoshi, Sugita, Kanji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195985/ https://www.ncbi.nlm.nih.gov/pubmed/34117218 http://dx.doi.org/10.1038/s41420-021-00523-y

Ejemplares similares

T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system
por: Tamai, Minori, et al.
Publicado: (2018)

Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis
por: Tamai, Minori, et al.
Publicado: (2022)

Association of relapse-linked ARID5B single nucleotide polymorphisms with drug resistance in B-cell precursor acute lymphoblastic leukemia cell lines
por: Tamai, Minori, et al.
Publicado: (2020)

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
por: Suzuki, Kazuhito, et al.
Publicado: (2023)

Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
por: Jung, Yoo Jin, et al.
Publicado: (2021)

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
por: Fionda, Cinzia, et al.
Publicado: (2015)

NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells
por: Somazu, Shinpei, et al.
Publicado: (2021)

Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL
por: Akahane, Koshi, et al.
Publicado: (2022)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Utility of ASNS gene methylation evaluated with the HPLC method as a pharmacogenomic biomarker to predict asparaginase sensitivity in BCP-ALL
por: Watanabe, Atsushi, et al.
Publicado: (2023)

Successful treatment of intractable gastrointestinal tract graft-vs-host disease with oral beclomethasone dipropionate in pediatric and young adult patients: Case reports
por: Akahane, Koshi, et al.
Publicado: (2022)

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
por: Bartlett, J B, et al.
Publicado: (2005)

Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide
por: Furihata, Hirotake, et al.
Publicado: (2020)

A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
por: Kopp, Katherine O., et al.
Publicado: (2023)

Decreased incidence of acute immune thrombocytopenia in children during the COVID-19 pandemic
por: Harama, Daisuke, et al.
Publicado: (2023)

Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers necrosis of B-precursor leukemia cells with high surface CD44 expression
por: Kasai, Shin, et al.
Publicado: (2017)

An IMiD-induced SALL4 degron system for selective degradation of target proteins
por: Yamanaka, Satoshi, et al.
Publicado: (2020)

309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations
por: Davis, Lorraine, et al.
Publicado: (2022)

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)
por: Liu, W M, et al.
Publicado: (2009)

Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?
por: Sponaas, Anne Marit, et al.
Publicado: (2021)

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma
por: Lien, I-Chia, et al.
Publicado: (2014)

iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
por: Bouguenina, Habib, et al.
Publicado: (2023)

The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma
por: Heider, Michael, et al.
Publicado: (2021)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
por: Gooding, Sarah, et al.
Publicado: (2022)

Inherited genetic variants associated with glucocorticoid sensitivity in leukaemia cells
por: Shinohara, Tamao, et al.
Publicado: (2020)

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis
por: Warsame, Rahma, et al.
Publicado: (2020)

Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
por: Cippitelli, Marco, et al.
Publicado: (2021)

IMiDs induce FAM83F degradation via an interaction with CK1α to attenuate Wnt signalling
por: Dunbar, Karen, et al.
Publicado: (2020)

Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia
por: Watanabe, Atsushi, et al.
Publicado: (2021)

Lenalidomide induces degradation of IKZF1 and IKZF3
por: Krönke, Jan, et al.
Publicado: (2014)

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
por: Thakurta, A, et al.
Publicado: (2014)

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase
por: An, Jian, et al.
Publicado: (2017)

Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma
por: Costacurta, Matteo, et al.
Publicado: (2020)

A comparison of peripheral blood stem cell collection outcomes for multiple myeloma; mobilization matters in the era of IMiD induction
por: Chandler, Thea, et al.
Publicado: (2023)

IMiDs Augment CD3-Bispecific Antibody–Induced CD8(+) T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production
por: Li, Ji, et al.
Publicado: (2023)

A New Strategy for the Old Challenge of Thalidomide: Systems Biology Prioritization of Potential Immunomodulatory Drug (IMiD)-Targeted Transcription Factors
por: Kowalski, Thayne Woycinck, et al.
Publicado: (2023)

Clofarabine exerts antileukemic activity against cytarabine‐resistant B‐cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression
por: Huang, Meixian, et al.
Publicado: (2018)

Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
por: Corti, Angelo, et al.
Publicado: (2010)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner
por: Dimopoulos, Konstantinos, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pkpbphuj9tum92sgo354o4e9cd